Clinical Trials Browser

Phase 2 × Malignant mesenchymal tumor × Doxorubicin × Clear all

NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Phase 2 Active not recruiting

65 enrolled

Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

NCT00410462 2014-08-08

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

Phase 2 Unknown

118 enrolled

GynecologicSarcoma

Malignant mesenchymal tumor, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Ovarian Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT00025441 2013-12-04

Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors

Phase 2 Completed

GynecologicSarcoma

Malignant mesenchymal tumor, Hemangiopericytoma, Malignant, Chondrosarcoma, Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Ovarian Neoplasms, Sarcoma, Neuroectodermal Tumors, Primitive, Peripheral, Desmoplastic Small Round Cell Tumor